Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

Canada: GW Pharmaceuticals Gets Canadian Approval for Cannabis

Bloomberg

Tuesday 19 Apr 2005

---

April 19 (Bloomberg) -- GW Pharmaceuticals Plc, a U.K. company developing
cannabis-based drugs, said it won Canadian approval to market its Sativex
spray for pain related to multiple sclerosis. Shares jumped as much as 14
percent.

Health Canada is the first regulatory agency to approve Sativex, Salisbury,
England-based GW Pharmaceuticals said in a Regulatory News Service
statement. GW and its marketing partner, Bayer AG, expect to introduce the
product in Canada in late spring, the company said.

Sativex is derived from two principle compounds found in the cannabis
plant, cannabidiol and Delta-9 Tetrahydrocannabinol, or THC, a psychoactive
ingredient.

GW Pharmaceuticals shares rose 13 pence, or 11 percent, to 134 pence as of
12:12 p.m. in London, after rising as high as 138.5 pence.

 

 

 

After you have finished reading this article you can click here to go back. 




This page was created by the Cannabis Campaigners' Guide.

Feel free to link to this page!